Melanoma | Topics

Artificial Intelligence Predicts Overall Survival in Patients With Advanced Melanoma
May 08, 2022

By reading CT scans, machine learning could aid investigators in improving treatment decision making.

Sotigalimab Plus Pembrolizumab Demonstrates Favorable Safety Profile in Metastatic Melanoma
April 13, 2022

The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.

Significant Improvement in PFS Noted With Second-Line Nivolumab Plus Ipilimumab in Advanced Melanoma
April 13, 2022

Patients with advanced melanoma receiving nivolumab plus ipilimumab in the second-line setting had significant improvement in progression-free survival.

Advanced Melanoma With Resistance to PD-1 Inhibition May Derive Benefit From BO-112 Plus Pembrolizumab
April 13, 2022

Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.

Early Data for PD-L1/IDO Peptide Vaccine Plus Standard PD-1 Inhibition Shows Promise in Metastatic Melanoma
April 08, 2022

Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
April 08, 2022

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Updated Analysis of Nivolumab Plus Ipilimumab Combos Highlights Long OS for Advanced Melanoma
March 23, 2022

The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.

Fast Track Designation Granted to Novel Immunostimulant 7HP349 in Anti–PD-1 Resistant Melanoma
March 21, 2022

7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.

FDA Approves Nivolumab/Relatlimab Combo for Unresectable or Metastatic Melanoma
March 18, 2022

Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.